HLA-A11 is associated with poor prognosis in childhood acute lymphoblastic leukemia (ALL). 1988

S Orgad, and I J Cohen, and Y Neumann, and R Vogel, and G Kende, and B Ramot, and R Zaizov, and E Gazit
Division of Transplantation Immunology, Sheba Medical Center, Tel-Hashomer, Israel.

A possible association between HLA antigens, susceptibility or resistance to leukemia, and responsiveness to treatment has been studied in 144 patients with childhood acute lymphoblastic leukemia (ALL) and compared to other prognostic factors, i.e. white blood cell (WBC) counts, age at onset, sex, ethnic origin, and cell surface markers. All sequentially newly diagnosed children (97) comprised the group for the prospective study (PSG) and were followed for 6 years. The group included 37 patients classified as T-ALL, 41 as CALLA+, 27 as NULL, 12 as B and pre-B, and 27 unclassified patients, who were diagnosed before 1980. During the follow-up period, 45 patients of the PSG died. Forty-seven patients designated long-term survivors (LTS) have been followed 6-20 years after diagnosis, having completed a 3-5 year course of anti-leukemia therapy, and having remained disease free thereafter. High WBC counts at diagnosis and T-cell-surface markers were associated with poor prognosis, as were enthnic origin and specific HLA antigens. Thus, there was one (1) a significant increase in HLA-A30 and a decrease in HLA B-14 in the PSG Jewish patients; and (2) a complete absence of HLA-ALL in LTS while, in the PSG, 8 of 9 HLA-All-positive patients died during the follow-up period. This suggests that HLA-All is associated with poor prognosis in childhood ALL.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

S Orgad, and I J Cohen, and Y Neumann, and R Vogel, and G Kende, and B Ramot, and R Zaizov, and E Gazit
July 1987, Blood,
S Orgad, and I J Cohen, and Y Neumann, and R Vogel, and G Kende, and B Ramot, and R Zaizov, and E Gazit
February 1999, Leukemia,
S Orgad, and I J Cohen, and Y Neumann, and R Vogel, and G Kende, and B Ramot, and R Zaizov, and E Gazit
August 2006, Leukemia research,
S Orgad, and I J Cohen, and Y Neumann, and R Vogel, and G Kende, and B Ramot, and R Zaizov, and E Gazit
January 2013, Leukemia & lymphoma,
S Orgad, and I J Cohen, and Y Neumann, and R Vogel, and G Kende, and B Ramot, and R Zaizov, and E Gazit
January 1994, Anticancer research,
S Orgad, and I J Cohen, and Y Neumann, and R Vogel, and G Kende, and B Ramot, and R Zaizov, and E Gazit
June 2015, Leukemia research,
S Orgad, and I J Cohen, and Y Neumann, and R Vogel, and G Kende, and B Ramot, and R Zaizov, and E Gazit
May 2009, Future oncology (London, England),
S Orgad, and I J Cohen, and Y Neumann, and R Vogel, and G Kende, and B Ramot, and R Zaizov, and E Gazit
January 2013, [Rinsho ketsueki] The Japanese journal of clinical hematology,
S Orgad, and I J Cohen, and Y Neumann, and R Vogel, and G Kende, and B Ramot, and R Zaizov, and E Gazit
August 1994, Leukemia,
S Orgad, and I J Cohen, and Y Neumann, and R Vogel, and G Kende, and B Ramot, and R Zaizov, and E Gazit
December 2021, Hematology (Amsterdam, Netherlands),
Copied contents to your clipboard!